Title:
PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING VIRAL INFECTIOUS DISEASES, CONTAINING EFAVIRENZ AND FLUOXETINE AS ACTIVE INGREDIENTS
Document Type and Number:
WIPO Patent Application WO/2023/058987
Kind Code:
A1
Abstract:
The present invention relates to a pharmaceutical composition for preventing or treating viral infectious diseases, containing efavirenz and fluoxetine as active ingredients. It has been identified that when a complex, mixture or combination of efavirenz and fluoxetine is administered or a complex, mixture or combination of efavirenz and fluoxetine, to which a biguanide-based compound metformin is added, is administered, antiviral efficacy against various zoonotic viruses including SARS-CoV-2 is remarkably higher than when each is administered alone, and thus efavirenz and fluoxetine, in addition to the biguanide-based compound, can be effectively used as active ingredients of a composition for preventing or treating viral infectious diseases.
Inventors:
PARK SOO HYUN (KR)
KIM SET BYEOL (KR)
KIM JEONG HOON (KR)
MO YOUNG WON (KR)
KIM SET BYEOL (KR)
KIM JEONG HOON (KR)
MO YOUNG WON (KR)
Application Number:
PCT/KR2022/014517
Publication Date:
April 13, 2023
Filing Date:
September 28, 2022
Export Citation:
Assignee:
FRONTBIO INC (KR)
International Classes:
A61K31/536; A61K31/138; A61K45/06; A61P25/24; A61P31/12
Foreign References:
| KR20170141774A | 2017-12-26 | |||
| KR20150022731A | 2015-03-04 | |||
| KR20210103426A | 2021-08-23 | |||
| KR101638156B1 | 2016-07-08 |
Other References:
DECHAUMES ARTHUR, NEKOUA MAGLOIRE PANDOUA, BELOUZARD SANDRINE, SANE FAMARA, ENGELMANN ILKA, DUBUISSON JEAN, ALIDJINOU ENAGNON KAZA: "Fluoxetine Can Inhibit SARS-CoV-2 In Vitro", MICROORGANISMS, vol. 9, no. 2, 9 February 2021 (2021-02-09), pages 339, XP093055724, DOI: 10.3390/microorganisms9020339
Attorney, Agent or Firm:
KIM, Bo Jung (KR)
Download PDF: